WO1997008551A1 - Procedes et anticorps permettant la detection de creatine kinase - Google Patents

Procedes et anticorps permettant la detection de creatine kinase Download PDF

Info

Publication number
WO1997008551A1
WO1997008551A1 PCT/US1996/013755 US9613755W WO9708551A1 WO 1997008551 A1 WO1997008551 A1 WO 1997008551A1 US 9613755 W US9613755 W US 9613755W WO 9708551 A1 WO9708551 A1 WO 9708551A1
Authority
WO
WIPO (PCT)
Prior art keywords
isoenzyme
assay
binding substance
antibody
isoenzymes
Prior art date
Application number
PCT/US1996/013755
Other languages
English (en)
Inventor
Robert F. Zuk
Maje B. Perryman
Original Assignee
First Medical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Medical, Inc. filed Critical First Medical, Inc.
Priority to AU67641/96A priority Critical patent/AU6764196A/en
Publication of WO1997008551A1 publication Critical patent/WO1997008551A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9123—Phosphotransferases in general with a nitrogenous group as acceptor (2.7.3), e.g. histidine kinases

Definitions

  • Patent 4,624,961 describes two-site immunoradiometric assays for detecting CK-MB isoenzyme where cross-reactivity is reduced by performing the assay in the presence of pooled human sera.
  • the detection of specific isoforms of the MM, BB and MB CK isoenzymes is described in the following U. S. Patent Nos. 4,810,639; 4,900,662; 5,202,234; 5,382,515;
  • the antibody will have a substantially equal binding affinity for each of the CK-MM, CK-BB, and CK-MB isoforms, and mitochondrial CK.
  • the use of such assays permits detection of total CK isoenzyme using only a single antibody which is cross-reactive with each of the three CK isoenzymes.
  • mixtures of antibodies specific for the M subunit and B subunit, respectively can be used for binding total CK isoenzyme in the methods of the present invention.
  • the total CK isoenzyme (including all three isoenzymes) and the CK-MB isoenzyme will be measured by reacting the sample with at least one binding substance which binds to the target enzyme, usually an antibody, an antibody fragment, or equivalent molecule, as described in more detail below.
  • at least one binding substance which binds to the target enzyme usually an antibody, an antibody fragment, or equivalent molecule, as described in more detail below.
  • binding substance and “specific binding substance” will refer to intact antibody molecules (immunoglobulins) as well as to portions of the antibody molecule which retain the ability to bind to epitopes on the target enzyme.
  • Such antibody portions include the Fab, Fab', and F(ab') 2 fragments of immunoglobulins.
  • numerous techniques have been prepared for recombinantly producing molecules having the binding specificities of antibodies.
  • an antibody molecule is prepared in a conventional manner, as described in more detail below, and the gene encoding the antibody molecule isolated. After sequencing the antibody gene, recombinant nucleic acids can be isolated or synthesized and used to prepare binding proteins by a variety of now conventional methods.
  • the epitope should be sufficiently sterically removed from the epitope which is bound to the solid phase to permit detection with the labeling reagent.
  • a mixture of antibodies specific for the M and B subunits may be employed, where the antibodies are attached to the same label.
  • Suitable labels will be of a type which are separately detectable within each of the reaction zones. After the initial steps of binding the CK isoenzyme and labeling the bound CK isoenzyme, it is necessary to separately detect the amount of isoenzyme bound within each reaction zone.
  • radio and enzyme labels that do not produce a localized signal will generally not be suitable for use in the present invention. Localized labels, such as fluorescent labels, luminescent labels, and the like will find particular use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des dosages ainsi que sur des anticorps permettant de détecter des enzymes créatines kinases (CK). Il est possible de déceler la présence d'une iso-enzyme CK complète à l'aide d'un anticorps spécifique d'un épitope dans la région conservée des sous-unités M et B d'iso-enzymes CK ainsi que de la CK mitochondriale. Il est possible d'établir le rapport de l'iso-enzyme CK-MB à l'iso-enzyme CK complète en utilisant un dispositif de dosage en phase solide pourvu d'une première et d'une seconde zone de réaction. Un anticorps spécifique des iso-enzymes CK dans leur totalité est présent dans la première zone de réaction alors qu'un anticorps spécifique de l'iso-enzyme CK-MB se trouve dans la seconde. Il est alors possible de faire réagir un échantillon de plasma ou de sérum provenant d'un seul patient avec la phase solide pour déterminer simultanément les quantités relatives d'iso-enzyme CK.
PCT/US1996/013755 1995-08-31 1996-08-26 Procedes et anticorps permettant la detection de creatine kinase WO1997008551A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU67641/96A AU6764196A (en) 1995-08-31 1996-08-26 Methods and antibodies for detecting creatine kinase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52204895A 1995-08-31 1995-08-31
US08/522,048 1995-08-31

Publications (1)

Publication Number Publication Date
WO1997008551A1 true WO1997008551A1 (fr) 1997-03-06

Family

ID=24079248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/013755 WO1997008551A1 (fr) 1995-08-31 1996-08-26 Procedes et anticorps permettant la detection de creatine kinase

Country Status (2)

Country Link
AU (1) AU6764196A (fr)
WO (1) WO1997008551A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136610A (en) * 1998-11-23 2000-10-24 Praxsys Biosystems, Inc. Method and apparatus for performing a lateral flow assay
EP1072889A1 (fr) * 1999-01-19 2001-01-31 International Reagents Corporation Procede d'analyse de l'activite de l'isozyme de la creatine kinase et reactif d'analyse
WO2002004950A2 (fr) * 2000-07-12 2002-01-17 Werner Naser Evaluation directe de rapports analyte/molecule de reference
WO2002008722A2 (fr) * 2000-07-12 2002-01-31 Werner Naser Evaluation directe de concentrations relatives de variants d'un epitope sur une molecule dimere
US6528323B1 (en) 1999-06-14 2003-03-04 Praxsys Biosystems, Inc. Bidirectional lateral flow test strip and method
EP1359162A2 (fr) * 2002-04-30 2003-11-05 International Reagents Corporation Anticorps anti-créatine kinase mitochondrienne
US7605004B2 (en) 2001-07-18 2009-10-20 Relia Diagnostic Systems Llc Test strip for a lateral flow assay for a sample containing whole cells

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116731185B (zh) * 2023-06-27 2023-11-10 安徽千诚生物技术有限公司 一种肌酸激酶同工酶抗体及线粒体ck检测试剂盒

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353982A (en) * 1980-04-10 1982-10-12 Hoffmann-La Roche Inc. Immunochemical assay for creatine kinase-MB isoenzyme
US5017687A (en) * 1988-03-10 1991-05-21 Virovahl, S.A. Peptides for the detection of HTLV-1 infection
US5210039A (en) * 1989-02-09 1993-05-11 Eastman Kodak Company Wash composition, test kit and their use to determine a herpes simplex viral antigen
US5290678A (en) * 1990-10-12 1994-03-01 Spectral Diagnostics Inc. Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5298406A (en) * 1992-09-14 1994-03-29 E. I. Du Pont De Nemours And Company Formulation for stabilizing enzymatic activity and immunoreactivity of creatine kinase and creatine kinase isoenzymes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353982A (en) * 1980-04-10 1982-10-12 Hoffmann-La Roche Inc. Immunochemical assay for creatine kinase-MB isoenzyme
US5017687A (en) * 1988-03-10 1991-05-21 Virovahl, S.A. Peptides for the detection of HTLV-1 infection
US5210039A (en) * 1989-02-09 1993-05-11 Eastman Kodak Company Wash composition, test kit and their use to determine a herpes simplex viral antigen
US5290678A (en) * 1990-10-12 1994-03-01 Spectral Diagnostics Inc. Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5298406A (en) * 1992-09-14 1994-03-29 E. I. Du Pont De Nemours And Company Formulation for stabilizing enzymatic activity and immunoreactivity of creatine kinase and creatine kinase isoenzymes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 14 November 1986, Vol. 140, No. 3, PERRYMAN et al., "Isolation and Sequence Analysis of a Full-Length cDNA for Human M Creatine Kinase", pages 981-989. *
MOLECULAR AND CELLULAR BIOCHEMISTRY, April/May 1994, Vols. 133/134, MUHLEBACH et al., "IV-2 Sequence Homology and Structure Predictions of the Creatine Kinase Isoenzymes", pages 245-262. *
N. TIETZ, "Textbook of Clinical Chemistry", published 1986, by W.B. SAUNDERS COMPANY (PHILADELPHIA), see pages 686-689, 698-699, 1820. *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136610A (en) * 1998-11-23 2000-10-24 Praxsys Biosystems, Inc. Method and apparatus for performing a lateral flow assay
EP1072889A1 (fr) * 1999-01-19 2001-01-31 International Reagents Corporation Procede d'analyse de l'activite de l'isozyme de la creatine kinase et reactif d'analyse
EP1072889A4 (fr) * 1999-01-19 2005-10-19 Int Reagents Corp Procede d'analyse de l'activite de l'isozyme de la creatine kinase et reactif d'analyse
US6586194B1 (en) * 1999-01-19 2003-07-01 International Reagents Corporation Method for assaying creatine kinase isozyme activity and assay reagent
US6528323B1 (en) 1999-06-14 2003-03-04 Praxsys Biosystems, Inc. Bidirectional lateral flow test strip and method
US7229839B2 (en) 1999-06-14 2007-06-12 Relia Diagnostic Systems, Llc Bidirectional lateral flow test strip and method
WO2002008722A2 (fr) * 2000-07-12 2002-01-31 Werner Naser Evaluation directe de concentrations relatives de variants d'un epitope sur une molecule dimere
WO2002008722A3 (fr) * 2000-07-12 2002-05-16 Werner Naser Evaluation directe de concentrations relatives de variants d'un epitope sur une molecule dimere
WO2002004950A3 (fr) * 2000-07-12 2002-04-18 Werner Naser Evaluation directe de rapports analyte/molecule de reference
WO2002004950A2 (fr) * 2000-07-12 2002-01-17 Werner Naser Evaluation directe de rapports analyte/molecule de reference
US7605004B2 (en) 2001-07-18 2009-10-20 Relia Diagnostic Systems Llc Test strip for a lateral flow assay for a sample containing whole cells
EP1359162A2 (fr) * 2002-04-30 2003-11-05 International Reagents Corporation Anticorps anti-créatine kinase mitochondrienne
EP1359162A3 (fr) * 2002-04-30 2004-01-14 International Reagents Corporation Anticorps anti-créatine kinase mitochondrienne

Also Published As

Publication number Publication date
AU6764196A (en) 1997-03-19

Similar Documents

Publication Publication Date Title
CA1303496C (fr) Dosage immunologique permettant de mesurer le ck-mm, pour la detection de l'infarctus du myocarde
JP4602321B2 (ja) 診断目的のための生物学的液体における中間領域プロアドレノメデュリン部分領域の測定およびこのような測定を行うためのイムノアッセイ
JP3197277B2 (ja) 一種類以上の免疫学的配位子の分析方法，その分析試薬およびそのキット
EP2064551B1 (fr) Procédé combinatoire de détection d'anticorps anti-virus de l'hépatite c et d'antigènes du virus de l'hépatite c
US5200318A (en) Diagnosis of IDDM with a panel of immunoreagents
KR102549704B1 (ko) Pivka-ii의 측정 방법, 및 pivka-ii 면역측정 시약 또는 키트의 제조 방법
US7763435B2 (en) Method for diagnosis of alzheimer's disease with determination of LASP-1 immunoreactivity
CA2674736A1 (fr) Marqueurs peptidiques pour le diagnostic de l'angiogenese
EP2074422A2 (fr) Methodes et trousses de detection de marqueurs du cancer de la prostate
EP1794593A2 (fr) Procedes et compositions de detection du cancer au moyen de composants de la particule spliceosomale u2
AU726738B2 (en) Diagnosis of epithelial cell abnormalities
US6248869B1 (en) Troponin I forms and use of the same
WO1997008551A1 (fr) Procedes et anticorps permettant la detection de creatine kinase
EP0940470A2 (fr) Protéine de fusion et sa utilisation pour la détection des anticorps liée au diabète mellitus insulinodépendant
US20020127602A1 (en) Troponin I polypeptide fragments and uses thereof
EP1877775A2 (fr) Detection de marqueurs biologiques carbohydrates
JP6122779B2 (ja) 抗ｗｔ１抗体の測定方法
JP2000513201A (ja) 上皮小体ホルモン様たんぱく質に関連する化合物および方法
KR20110134649A (ko) 제1형 당뇨병성 신증 진단용 단백질성 마커
CA2409208C (fr) Procede d'examen d'une maladie liee au gene wt1
CN108948173B (zh) 一种瓜氨酸修饰肽及其应用
CN108948174B (zh) 一种瓜氨酸修饰肽及其应用
JPH09229933A (ja) ｐ５３蛋白質に対する自己抗体検出法
JPH10300749A (ja) コラーゲン断片を認識する抗体
JP2001343389A (ja) Ｍｄｍ２に対する自己抗体の測定によるがんの検査方法およびその試薬

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA